APRI 21 0.03 MG — DIN 02317192
ETHINYL ESTRADIOL : 0.03 MG DESOGESTREL : 0.15 MG · TEVA CANADA LIMITED · TABLET · wholesale supply in Canada
Health Canada status: MARKETED
What is APRI 21?
APRI 21 0.03 MG contains ETHINYL ESTRADIOL : 0.03 MG DESOGESTREL : 0.15 MG. It is listed in the Health Canada Drug Product Database under DIN 02317192, held by TEVA CANADA LIMITED, supplied as TABLET for ORAL administration. Health Canada currently lists it as marketed, status dated 28-May-2015. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is APRI 21 used for?
APRI® (desogestrel / ethinyl estradiol tablets, USP) is indicated for: Conception control
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
How much does Desogestrel And Estrogen cost around the world?
Desogestrel And Estrogen is listed on 12 of the national price registers Nexara ingests. Each country publishes on a different basis, so those figures are not comparable with one another — or with a Canadian wholesale price.
What a market publishes matters more than the number it publishes. Bahrain publishes a retail (max); Brazil publishes a preco fabrica (ex-factory ceiling); Greece publishes a producer price (ex-factory). Comparing an ex-factory ceiling against a pharmacy public price tells you nothing about either, and comparing either against a Canadian landed cost tells you less.
| Market | Price basis published there | Brands | Packs listed | Range |
|---|---|---|---|---|
| Brazil | preco fabrica (ex-factory ceiling) | 12 | 46 | BRL███.██ |
| Spain | PVP con IVA (public price) | 16 | 16 | EUR███.██ |
| Saudi Arabia | public | 8 | 11 | SAR███.██ |
| Sweden | AIP (pharmacy purchase price) | 6 | 11 | SEK███.██ |
| Norway | max AUP (pharmacy retail) | 5 | 5 | NOK███.██ |
| South Africa | single exit price | 4 | 4 | ZAR███.██ |
| Bahrain | retail (max) | 3 | 3 | BHD███.██ |
| United Arab Emirates | public | 2 | 2 | AED███.██ |
| United Kingdom | hospital | 1 | 1 | GBP███.██ |
| Greece | producer price (ex-factory) | 1 | 1 | EUR███.██ |
| Morocco | PPV (public price) | 1 | 1 | MAD███.██ |
| Romania | max producer price | 1 | 1 | RON███.██ |
102 pack listings across 60 brand entries and 11 price bases, refreshed 07 Sep 2026. Ranges span every Desogestrel And Estrogen pack in that market, so a high figure is usually a larger pack rather than the same product.
Canada publishes no comparable public list price. For a delivered Canadian price on a licensed account, verify your licence — it takes about a minute.
Is there a generic Desogestrel And Estrogen in Canada, and who makes it?
Every market authorization holder with a Canadian DIN for this molecule, and how many of their listings Health Canada currently shows as marketed.
8 holders have a Canadian DIN containing Desogestrel And Estrogen, across 16 DINs, of which 10 are currently marketed. Marketed count is the number that matters: an approval that is not marketed cannot be bought.
| Market authorization holder | DINs | Marketed | Brand names | Position |
|---|---|---|---|---|
| AMBICARE PHARMACEUTICALS INC. | 2 | 2 | MILEY 21, MILEY 28 | Sourceable in Canada |
| APOTEX INC | 2 | 2 | MIRVALA 21, MIRVALA 28 | Sourceable in Canada |
| MYLAN PHARMACEUTICALS ULC | 2 | 2 | FREYA 21, FREYA 28 | Sourceable in Canada |
| ORGANON CANADA INC. | 2 | 2 | MARVELON 21, MARVELON 28 | Sourceable in Canada |
| TEVA CANADA LIMITED | 2 | 2 | APRI 21, APRI 28 | Sourceable in Canada |
| ACTAVIS PHARMA COMPANY | 2 | 0 | RECLIPSEN 21, RECLIPSEN 28 | No marketed DIN |
| JANSSEN INC | 2 | 0 | ORTHO-CEPT TABLETS (21 DAY), ORTHO-CEPT TABLETS (28 DAY) | No marketed DIN |
| NOVOPHARM LIMITED | 2 | 0 | MARFEM 21, MARFEM 28 | No marketed DIN |
Health Canada’s Drug Product Database does not flag which listing is the originator and which are subsequent-entry products, so Nexara does not label them here. Interchangeability is determined provincially, not federally — confirm for your province before a formulary switch. Nexara can confirm which of these is actually obtainable, and on what lead time, per order.
How is it supplied and stored?
Pack configuration, storage class and the handling constraints that drive cold-chain planning. One DIN can cover more than one pack size, and the pack — not the DIN — is what gets priced, shipped and invoiced.
| Strength on the label | 0.03 MG |
|---|---|
| Dosage form | TABLET |
| Route | ORAL |
| Pack configuration (monograph) | APRI® 21: Each sachet contains an Aclar blister dispenser with 21 round rose active tablets. APRI® 28: Each sachet contains an Aclar blister dispenser with 21 round rose active tablets and 7 round white inert tablets. |
| Storage | null |
Before an order line is unambiguous Nexara needs the strength, the pack size and the presentation.
Substance and classification
| Active substance | Desogestrel And Estrogen |
|---|---|
| ATC code | G03AA09 |
| AHFS class | 68:12.00 |
| Biosimilar biologic | No |
Health Canada record and identifiers
The regulatory facts straight from the Drug Product Database, plus every identifier form Nexara accepts on a purchase order. A DIN written without its leading zeros is the commonest reason an order line fails to match.
| DIN (8-digit, as used in ordering) | 02317192 |
|---|---|
| DIN (unpadded, as printed on some documents) | 2317192 |
| Brand name | APRI 21 |
| Generic / active ingredient | ETHINYL ESTRADIOL : 0.03 MG DESOGESTREL : 0.15 MG |
| Market authorization holder | TEVA CANADA LIMITED |
| Health Canada schedule | Prescription |
| ATC code | G03AA09 |
| ATC anatomical main group | G — Genito-urinary system and sex hormones |
| ATC therapeutic subgroup | G03AA |
| Current status | MARKETED |
| Status date | 28-May-2015 |
| Original market date | 2008-09-29 00:00:00 |
| Status source | Live Health Canada DPD sync |
Verify on the primary sources
What can be used instead?
Alternatives on every axis a buyer actually considers — the same molecule in another presentation, the same class, an adjacent class, or a fixed-dose combination. Every row is led by the marketed DIN count, because that is what can be bought this week.
1 · Same molecule, other Canadian presentations
10 of 16 Canadian DINs for this molecule are currently marketed. Marketed products are listed first.
| Product | Strength | Form | Holder | Health Canada status | DIN |
|---|---|---|---|---|---|
| APRI 28 | 0.15 MG | TABLET | TEVA CANADA LIMITED | MARKETED | 02317206 |
| FREYA 21 | 0.15 MG | TABLET | MYLAN PHARMACEUTICALS ULC | MARKETED | 02396491 |
| FREYA 28 | 0.03 MG | TABLET | MYLAN PHARMACEUTICALS ULC | MARKETED | 02396610 |
| MARVELON 21 | 0.03 MG | TABLET | ORGANON CANADA INC. | MARKETED | 02042487 |
| MARVELON 28 | 0.15 MG | TABLET | ORGANON CANADA INC. | MARKETED | 02042479 |
| MILEY 21 | 0.15 MG | TABLET | AMBICARE PHARMACEUTICALS INC. | MARKETED | 02556553 |
| MILEY 28 | 0.15 MG | TABLET | AMBICARE PHARMACEUTICALS INC. | MARKETED | 02556561 |
| MIRVALA 21 | 0.1500 MG | TABLET | APOTEX INC | MARKETED | 02410249 |
| MIRVALA 28 | 0.0300 MG | TABLET | APOTEX INC | MARKETED | 02410257 |
| MARFEM 21 | 0.03 MG | TABLET | NOVOPHARM LIMITED | CANCELLED PRE MARKET | 02328828 |
2 · Same class — other molecules in ATC G03AA
| Molecule | Canadian brands | DINs | Marketed | Sourceable |
|---|---|---|---|---|
| Levonorgestrel And Estrogen | ALESSE 21 · ALESSE 28 · ALYSENA 21 · ALYSENA 28 · +22 more | 26 | 18 | Yes |
| Drospirenone And Estrogen | DROSPIRENONE AND ETHINYL ESTRADIOL TABLETS · DROSPIRENONE AND ETHINYL ESTRADIOL TABLETS 21 · DROSPIRENONE AND ETHINYL ESTRADIOL TABLETS 28 · DROSPIRENONE AND ETHINYL ESTRADIOL TABLETS USP · +16 more | 20 | 10 | Yes |
| Desogestrel And Estrogen | APRI 21 · APRI 28 · FREYA 21 · FREYA 28 · +12 more | 16 | 10 | Yes |
| Norethisterone And Estrogen | BREVICON 0.5/35 21 TAB · BREVICON 0.5/35 28 TAB · BREVICON 0.5/35 TABLETS (21-DAY PACK) · BREVICON 0.5/35 TABLETS (28-DAY PACK) · +19 more | 25 | 6 | Yes |
| Norelgestromin And Estrogen | EVRA · EVRA -(6/0.75) | 2 | 1 | Yes |
| Drospirenone And Estetrol | NEXTSTELLIS | 1 | 1 | Yes |
| Norgestimate And Estrogen | CYCLEN TABLETS (21 DAY) · CYCLEN TABLETS (28 DAY) · PREVIFEM (21DAY) · PREVIFEM (28DAY) · +2 more | 6 | 0 | Not in Canada |
| Norgestrel And Estrogen | LO-FEMENAL 21 TABLETS · OVRAL 21 · OVRAL 21 TAB · OVRAL 28 TABLETS · +1 more | 5 | 0 | Not in Canada |
| Etynodiol And Estrogen | DEMULEN 30 (21 DAY PACK) · DEMULEN 30 (28 DAY PACK) · DEMULEN 50 (21 DAY PACK) · DEMULEN 50 (28 DAY PACK) | 4 | 0 | Not in Canada |
A molecule with zero marketed DINs cannot be sourced domestically, however many approvals it holds — if one of these sits on a formulary or in an older protocol, that is the line to check.
3 · Adjacent classes in ATC G03A
| ATC subgroup | Molecules | DINs | Marketed |
|---|---|---|---|
| G03AB | Desogestrel And Estrogen · Dienogest And Estrogen · Levonorgestrel And Estrogen · Norethisterone And Estrogen · Norgestimate And Estrogen · +2 more | 40 | 14 |
| G03AC | Drospirenone · Etonogestrel · Levonorgestrel · Medroxyprogesterone · Norethisterone · +1 more | 13 | 6 |
| G03AD | Levonorgestrel · Ulipristal | 14 | 5 |
Not clinical advice. These tables describe what can be supplied in Canada, not what should be prescribed. Substitution within or across classes is a prescriber and pharmacist decision, and interchangeability is determined provincially.
What else is APRI 21 called?
The same molecule, Desogestrel And Estrogen, is registered under other names elsewhere. Buyers and prescribers searching from outside Canada — or working from a foreign prescription or tender document — often know it by one of these:
| Name | Script | Registered in |
|---|---|---|
| DESOGESTREL | Latin | Brazil |
| Cerazette | Latin | Bahrain, Brazil, Morocco, Norway |
| CARELI | Latin | Brazil |
| KELLY | Latin | Brazil |
| MAYSA | Latin | Brazil |
| Vinelle | Latin | Norway, Sweden |
| Azalia | Latin | Sweden |
| Desogestrel Sandoz | Latin | Sweden |
| Gestrina | Latin | Sweden |
| GRACIAL TABLET | Latin | Saudi Arabia |
| Marvelon | Latin | Bahrain, South Africa |
| MARVELON TAB | Latin | Saudi Arabia |
| MELIK | Latin | Brazil |
| NACTALI | Latin | Brazil |
| ONUA | Latin | Brazil |
Names are taken from national medicine registers and published price lists. A product registered abroad is not authorized for sale in Canada unless it holds its own DIN; import is possible only through the routes Health Canada permits.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address. Patients and unlicensed buyers are routed to a partner pharmacy.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Why is there no price on this page?
Nexara quotes a delivered Canadian price per order, against a verified licence. Foreign list prices are published on incompatible bases and are not a guide to what any buyer can obtain here, so this page shows which markets list the molecule and on what basis, and nothing more.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.